Viewing Opinion | StockChase

Cipher Pharmeuticals (CPH-T) opinion on 2018-05-15

Last Price Recorded: 3.5100 on 2018-05-19

ON STOCKCHASE SINCE Dec 2014

Healthcare
Healthcare
PAST TOP PICK

James Hodgins
Cipher Pharmeuticals was $3.550 at time of opinion
Owned : Yes

(A Top Pick March 26, 2018. Down 16%). This initially popped higher but they preannounced a poor quarter because the market had been stuffed by a promotion. This quarter will be a little weak for the same reason but after that, it will do better. Cipher historically focused on dermatology. With their purchase of Cardiome Pharma Corp’s Canadian assets, they will now also be focused on arrhythmia and other cardiovascular conditions addressed by Cordiome’s drugs. He loves Cipher here. He thinks it is trading at half what specialty pharma companies, like Knight, sell for. He sees this as a good takeover target for Knight and sees it as a potential double.

UNKNOWN

All opinions for CPH-T (12)

1 BUY
5 COMMENT
2 DON'T BUY
1 HOLD
1 PAST TOP PICK
1 TOP PICK
1 WATCH
View All

More experts covering CPH-T

SAVE
Add CPH-T to Watch List

All opinions for CPH-T (12)

1 BUY
5 COMMENT
2 DON'T BUY
1 HOLD
1 PAST TOP PICK
1 TOP PICK
1 WATCH
View All

More experts covering CPH-T

SAVE
Add CPH-T to Watch List

Last 60 Days Opinions

TOP PICK
1 month ago

No Comments.


You must be logged in to comment.

Successfully Saved Company